A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3‐6 months after starting treatment. We present a 64‐year‐old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyunsam, Lee, Jeongmin, Ha, Jeonghoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132132/
https://www.ncbi.nlm.nih.gov/pubmed/30214745
http://dx.doi.org/10.1002/ccr3.1644
Descripción
Sumario:Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3‐6 months after starting treatment. We present a 64‐year‐old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

Ejemplares similares